Inclusion Criteria:

          -  Patients with one of the high risk myeloid diseases as outlined below. Patients must
             have ≤ 5% blasts on the last BM evaluation prior to starting the conditioning regimen.
             Diseases included on this protocol include:

               1. Acute Myeloid Leukemia (AML) in CR1 with intermediate or high risk features as
                  defined below:

                  °Cytogenetic abnormalities which are not considered "good risk" cytogenetic
                  features (i.e t(8:21), t(15:17), inv 16 without c-kit mutations.

                  And/or

                    -  Therapy related AML with history of antineoplastic therapy (radiation and/or
                       chemotherapy) And/or

                    -  Normal karyotype with mutations of FLT3, RUNX1, TP53 mutation, ASXL1 or any
                       others that are considered to be high risk

               2. AML in ≥ 2nd remission

               3. Myelodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN overlap
                  syndrome with:

                  °International prognostic scoring system risk score INT-2 or high risk at the
                  time of transplant evaluation.

                  And/or

                    -  Any risk category if life-threatening cytopenia exists And/or

                    -  Karyotype or genomic changes that indicate high risk for progression to
                       acute myelogenous leukemia, including abnormalities of chromosome 7 or 3,
                       mutations of TP53, or complex or monosomal karyotype.

               4. Chronic myelomonocytic leukemia (CMML)

               5. Chronic myeloid leukemia (CML) with the following features:

                  °Patients who have failed or are intolerant to BCR-ABL tyrosine kinase
                  inhibitors.

                  And/or

                  °CML with BCR-ABL mutation consistent with poor response to tyrosine kinase
                  inhibition (e.g T351l mutation)

               6. Patients with severe aplastic anemia

          -  Chronic lymphocytic leukemia (CLL) with high risk disease as defined by the EBMT
             consensus criteria.

          -  Non-Hodgkin lymphoma meeting both of the following criteria:

               -  Responding to therapy prior to enrollment.

               -  Relapse after prior autologous bone marrow transplant or are ineligible for
                  autologous bone marrow transplant.

          -  Multiple Myeloma with disease in the following categories:

               -  Patients with relapsed multiple myeloma following autologous stem cell
                  transplantation who have achieved at least partial response following additional
                  chemotherapy

               -  Patients with high risk cytogenetics at diagnosis must have achieved at least a
                  partial response following autologous stem cell transplantation. Patients must
                  have complex karyotype, del17p, t4;14, and/or t14;16 by FISH and/or del13 by
                  karyotyping.

          -  Each patient must be willing to participate as a research participant and must sign an
             informed consent form.

          -  Organ Function and Performance Status Criteria:

               1. Patients be ≥ 18 years old.

               2. Patients must have a Karnofsky (adult) or Performance Status ≥ 70%.

               3. Patients must have adequate organ function measured by:

                    -  Cardiac: asymptomatic or if symptomatic, then LVEF at rest must be ≥ 40% and
                       must improve with exercise.

                    -  Hepatic: < 5x ULN ALT and < 2x ULN total serum bilirubin, unless there is
                       congenital benign hyperbilirubinemia.

                    -  Renal: CrCl >30ml/min (measured or calculated/estimated).

                    -  Pulmonary: asymptomatic or if symptomatic, DLCO > 50% of predicted
                       (corrected for hemoglobin)

        Exclusion Criteria:

          -  Prior allogenic hematopoietic stem cell transplantation

          -  Prior radiation therapy with 400cGY or more of TBI

          -  BM with increased fibrosis (Reticulin stain > 1/3)

          -  Active and uncontrolled infection at time of transplantation

          -  HIV infection

          -  Seropositivity for HTLV-1

          -  Inadequate performance status/ organ function

          -  Pregnancy or breast feeding

          -  Patient or guardian unable to give informed consent or unable to comply with the
             treatment protocol including appropriate supportive care, follow-up, and research
             tests.

        Donor Inclusion and Exclusion Criteria:

          -  Must be a 10/10 HLA genotypically match related or unrelated donor at all A, B, C,
             DRB1, and DQB1 loci, as tested by DNA analysis

          -  Able to provide informed consent for the donation process per institutional standards

          -  Meet standard criteria for donor collection as defined by the National Marrow Donor
             Program Guidelines